USFDA10 Nov 2025, 12:07 pm
Marksans Pharma Ltd Receives Zero Form 483 Observations in US FDA cGMP Inspection
AI Summary
Marksans Pharma Ltd has announced that the US FDA has conducted a cGMP inspection of the company's second manufacturing facility located at Plot No. A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa. The inspection, which took place from 3rd to 7th November 2025, concluded with zero Form 483 observations. This successful outcome is a testament to Marksans Pharma's commitment to product quality and regulatory compliance.
Key Highlights
- US FDA conducted cGMP inspection at Marksans Pharma's second manufacturing facility in Goa
- Inspection concluded with zero Form 483 observations
- This is a testament to Marksans Pharma's commitment to product quality and regulatory compliance